Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies
European Journal of Cancer2017Vol. 76, pp. 68–75
Citations Over TimeTop 10% of 2017 papers
Maguy Del Rio, Caroline Mollévi, Frédéric Bibeau, Nadia Vié, Janick Sèlves, Jean‐François Emile, Pascal Roger, Céline Gongora, Jacques Robert, N. Tubiana-Mathieu, Marc Ychou, Pierre Martineau
Related Papers
- → Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial(2010)52 cited
- → UGT1A1*28 Genotype Predicts Gastrointestinal Toxicity in Patients Treated With Intermediate-Dose Irinotecan(2009)34 cited
- → Irinotecan and colorectal cancer: the role of p53, VEGF-C and α-B-crystallin expression(2009)14 cited
- → Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients(2001)56 cited
- → Comprehensive genetic definition of susceptibility to toxic side effects of irinotecan in mice.(2015)